Limitations
/metastatic gastroesophageal, urothelial cancers
In the heterogeneous population of advanced /metastatic gastroesophageal, gastric and urothelial cancers differential tolerance to study medications was noted. In this small study with five patients, we did not escalate to higher doses due to early study closure. This treatment strategy deserves further dosing and efficacy investigation in larger disease-specific patient populations.